Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission

David I. Marks, Waleska S. Pérez, Wensheng He, Mei Jie Zhang, Michael R. Bishop, Brian J. Bolwell, Christopher N. Bredeson, Edward A. Copelan, Robert Peter Gale, Vikas Gupta, Gregory A. Hale, Luis M. Isola, Ann A. Jakubowski, Armand Keating, Thomas R. Klumpp, Hillard M. Lazarus, Jane L. Liesveld, Richard Maziarz, Philip L. Mccarthy, Mitchell SabloffGary Schiller, Jorge Sierra, Martin S. Tallman, Edmund K. Waller, Peter H. Wiernik, Daniel J. Weisdorf

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. Median age was 33 years (range, 16-59 years). A total of 50% had a white blood cell count (WBC) more than 30 ×10 9/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia. A total of 41% were HLA well-matched, 41% partially matched with their donors, and 18% were HLA-mismatched. At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graftversus-host disease were 50%, 25%, and 43%, respectively. Five-year treatmentrelated mortality (TRM), relapse, and overall survival were 42%, 20%, and 39%, respectively. In multivariate analyses, TRM was significantly higher with HLAmismatched donors and T-cell depletion. Relapse risk was higher if the diagnostic WBC was more than 100 ×10 9/L. Factors associated with poorer survival included WBC more than 100 × 10 9/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion. Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results.

Original languageEnglish (US)
Pages (from-to)426-434
Number of pages9
JournalBlood
Volume112
Issue number2
DOIs
StatePublished - Jul 15 2008

Fingerprint

Unrelated Donors
Transplants
T-cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blood
Leukocyte Count
Mortality
Recurrence
Tissue Donors
T-Lymphocytes
T-Cell Leukemia
Survival
Treatment Failure
Cytomegalovirus
Cells
Cytogenetics
Multivariate Analysis
Transplantation
Incidence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Marks, D. I., Pérez, W. S., He, W., Zhang, M. J., Bishop, M. R., Bolwell, B. J., ... Weisdorf, D. J. (2008). Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood, 112(2), 426-434. https://doi.org/10.1182/blood-2007-12-128918

Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission. / Marks, David I.; Pérez, Waleska S.; He, Wensheng; Zhang, Mei Jie; Bishop, Michael R.; Bolwell, Brian J.; Bredeson, Christopher N.; Copelan, Edward A.; Gale, Robert Peter; Gupta, Vikas; Hale, Gregory A.; Isola, Luis M.; Jakubowski, Ann A.; Keating, Armand; Klumpp, Thomas R.; Lazarus, Hillard M.; Liesveld, Jane L.; Maziarz, Richard; Mccarthy, Philip L.; Sabloff, Mitchell; Schiller, Gary; Sierra, Jorge; Tallman, Martin S.; Waller, Edmund K.; Wiernik, Peter H.; Weisdorf, Daniel J.

In: Blood, Vol. 112, No. 2, 15.07.2008, p. 426-434.

Research output: Contribution to journalArticle

Marks, DI, Pérez, WS, He, W, Zhang, MJ, Bishop, MR, Bolwell, BJ, Bredeson, CN, Copelan, EA, Gale, RP, Gupta, V, Hale, GA, Isola, LM, Jakubowski, AA, Keating, A, Klumpp, TR, Lazarus, HM, Liesveld, JL, Maziarz, R, Mccarthy, PL, Sabloff, M, Schiller, G, Sierra, J, Tallman, MS, Waller, EK, Wiernik, PH & Weisdorf, DJ 2008, 'Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission', Blood, vol. 112, no. 2, pp. 426-434. https://doi.org/10.1182/blood-2007-12-128918
Marks, David I. ; Pérez, Waleska S. ; He, Wensheng ; Zhang, Mei Jie ; Bishop, Michael R. ; Bolwell, Brian J. ; Bredeson, Christopher N. ; Copelan, Edward A. ; Gale, Robert Peter ; Gupta, Vikas ; Hale, Gregory A. ; Isola, Luis M. ; Jakubowski, Ann A. ; Keating, Armand ; Klumpp, Thomas R. ; Lazarus, Hillard M. ; Liesveld, Jane L. ; Maziarz, Richard ; Mccarthy, Philip L. ; Sabloff, Mitchell ; Schiller, Gary ; Sierra, Jorge ; Tallman, Martin S. ; Waller, Edmund K. ; Wiernik, Peter H. ; Weisdorf, Daniel J. / Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission. In: Blood. 2008 ; Vol. 112, No. 2. pp. 426-434.
@article{1a946044c207449e8f7de09a07a8f6bd,
title = "Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission",
abstract = "We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. Median age was 33 years (range, 16-59 years). A total of 50{\%} had a white blood cell count (WBC) more than 30 ×10 9/L, 18{\%} extramedullary disease, 42{\%} achieved CR more than 8 weeks from diagnosis, 25{\%} had adverse cytogenetics, and 19{\%} had T-cell leukemia. A total of 41{\%} were HLA well-matched, 41{\%} partially matched with their donors, and 18{\%} were HLA-mismatched. At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graftversus-host disease were 50{\%}, 25{\%}, and 43{\%}, respectively. Five-year treatmentrelated mortality (TRM), relapse, and overall survival were 42{\%}, 20{\%}, and 39{\%}, respectively. In multivariate analyses, TRM was significantly higher with HLAmismatched donors and T-cell depletion. Relapse risk was higher if the diagnostic WBC was more than 100 ×10 9/L. Factors associated with poorer survival included WBC more than 100 × 10 9/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion. Nearly 40{\%} of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results.",
author = "Marks, {David I.} and P{\'e}rez, {Waleska S.} and Wensheng He and Zhang, {Mei Jie} and Bishop, {Michael R.} and Bolwell, {Brian J.} and Bredeson, {Christopher N.} and Copelan, {Edward A.} and Gale, {Robert Peter} and Vikas Gupta and Hale, {Gregory A.} and Isola, {Luis M.} and Jakubowski, {Ann A.} and Armand Keating and Klumpp, {Thomas R.} and Lazarus, {Hillard M.} and Liesveld, {Jane L.} and Richard Maziarz and Mccarthy, {Philip L.} and Mitchell Sabloff and Gary Schiller and Jorge Sierra and Tallman, {Martin S.} and Waller, {Edmund K.} and Wiernik, {Peter H.} and Weisdorf, {Daniel J.}",
year = "2008",
month = "7",
day = "15",
doi = "10.1182/blood-2007-12-128918",
language = "English (US)",
volume = "112",
pages = "426--434",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Unrelated donor transplants in adults with philadelphia-negative acute lymphoblastic leukemia in first complete remission

AU - Marks, David I.

AU - Pérez, Waleska S.

AU - He, Wensheng

AU - Zhang, Mei Jie

AU - Bishop, Michael R.

AU - Bolwell, Brian J.

AU - Bredeson, Christopher N.

AU - Copelan, Edward A.

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Hale, Gregory A.

AU - Isola, Luis M.

AU - Jakubowski, Ann A.

AU - Keating, Armand

AU - Klumpp, Thomas R.

AU - Lazarus, Hillard M.

AU - Liesveld, Jane L.

AU - Maziarz, Richard

AU - Mccarthy, Philip L.

AU - Sabloff, Mitchell

AU - Schiller, Gary

AU - Sierra, Jorge

AU - Tallman, Martin S.

AU - Waller, Edmund K.

AU - Wiernik, Peter H.

AU - Weisdorf, Daniel J.

PY - 2008/7/15

Y1 - 2008/7/15

N2 - We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. Median age was 33 years (range, 16-59 years). A total of 50% had a white blood cell count (WBC) more than 30 ×10 9/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia. A total of 41% were HLA well-matched, 41% partially matched with their donors, and 18% were HLA-mismatched. At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graftversus-host disease were 50%, 25%, and 43%, respectively. Five-year treatmentrelated mortality (TRM), relapse, and overall survival were 42%, 20%, and 39%, respectively. In multivariate analyses, TRM was significantly higher with HLAmismatched donors and T-cell depletion. Relapse risk was higher if the diagnostic WBC was more than 100 ×10 9/L. Factors associated with poorer survival included WBC more than 100 × 10 9/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion. Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results.

AB - We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. Median age was 33 years (range, 16-59 years). A total of 50% had a white blood cell count (WBC) more than 30 ×10 9/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia. A total of 41% were HLA well-matched, 41% partially matched with their donors, and 18% were HLA-mismatched. At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graftversus-host disease were 50%, 25%, and 43%, respectively. Five-year treatmentrelated mortality (TRM), relapse, and overall survival were 42%, 20%, and 39%, respectively. In multivariate analyses, TRM was significantly higher with HLAmismatched donors and T-cell depletion. Relapse risk was higher if the diagnostic WBC was more than 100 ×10 9/L. Factors associated with poorer survival included WBC more than 100 × 10 9/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion. Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results.

UR - http://www.scopus.com/inward/record.url?scp=47649095760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649095760&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-12-128918

DO - 10.1182/blood-2007-12-128918

M3 - Article

C2 - 18398065

AN - SCOPUS:47649095760

VL - 112

SP - 426

EP - 434

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -